Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Authors: Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo
Nature Reviews Neurology, January 2020

Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been marked by disappointment, es…

Cannabis in Parkinson’s Disease: Hype or help?

Authors: Tina Mainka, Jan Stork, Ute Hidding, Carsten Buhmann
Fortschritte der Neurologie · Psychiatrie, February 2018

Cannabis buds and extracts as well as synthetic cannabinoids have been available on prescription to patients with severe diseases since March 2017, with the costs covered by health insurance companies.The prescription of medical marihuana is not restricted to specific symptoms…

Medical Cannabis in Parkinson Disease: Real-Life Patients’ Experience.

Authors: Yacov Balash, Lihi Bar-Lev Schleider, Amos Korczyn, Herzel Shabtai, Judith Knaani, et al
Clinical Neuropharmacology, November/December 2017

BACKGROUND: The use of medical cannabis (MC) is controversial. Support for its benefits is based on small clinical series. OBJECTIVE: The aim of this study was to report the results of a standardized interview study that retrospectively assessed the effects of MC on symptoms o…

Cannabinoids in Parkinson’s Disease.

Authors: Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, Ennio Iezzi
Cannabis and Cannabinoid Research, February 2017

The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably compl…

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.

Authors: Itay Lotan, Therese Treves, Yaniv Roditi, Ruth Djaldetti
Clinical Neuropharmacology, March-April 2014

OBJECTIVE: The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess…

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Authors: Antonio Waldo Zuardi
Brazilian Journal of Psychiatry, September 2008

OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1…

Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms.

Authors: Katerina Venderova, Evzen Růzicka, Viktor Vorısek, Peter Visnovsky
Movement Disorders, September 2004

An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit.